Start Here How HIV and kidney health interact
The short version: The kidneys quietly filter your blood 24 hours a day, and HIV plus certain HIV medications (especially tenofovir disoproxil fumarate, or TDF) can put them under stress. Chronic kidney disease is more common in people living with HIV than in the general population, but with routine monitoring (creatinine, eGFR, urine protein) and the right ART choice most kidney problems are caught early or avoided entirely. What follows is what to watch for, which labs matter, and when to talk to your provider about switching regimens.
← Learning HubWhy People Living with HIV Have Higher Kidney Disease Risk
Chronic kidney disease (CKD) is significantly more common in people living with HIV than in the general population. The size of the difference varies by population, treatment history, and other risk factors; a single multiplier does not apply to everyone. The EuroSIDA study cited here examined kidney disease and antiretroviral exposure among people with HIV[1]. This elevated risk comes from multiple sources — and understanding them is the first step toward protecting kidney function long-term.
The multiple drivers of kidney risk in people living with HIV
- HIV itself: The virus directly infects kidney cells and causes chronic inflammation that damages kidney tissue. Even with viral suppression, residual immune activation can continue to affect kidney function.
- Antiretroviral medications: Certain ART medications — particularly tenofovir disoproxil fumarate (TDF) — are associated with kidney tubular toxicity and reduced glomerular filtration rate in some patients, especially those with pre-existing risk factors.
- Hypertension: High blood pressure is both more common in people living with HIV and one of the leading causes of CKD. HIV-associated inflammation contributes to hypertension, and certain ART regimens can affect blood pressure.
- Diabetes: Diabetic nephropathy is the leading cause of CKD in the general population — and people living with HIV have elevated diabetes risk from both HIV itself and some ART medications' metabolic effects.
- Hepatitis C coinfection: HCV independently damages the kidneys through immune complex deposition. Anyone living with HIV who also has untreated HCV faces compounded kidney risk.
- Race: Black people living with HIV face particularly elevated CKD risk — partly due to the APOL1 gene variants more common in people of West African ancestry, which dramatically increase susceptibility to HIV-associated nephropathy (HIVAN).
- Aging: Normal aging reduces kidney function. When HIV-related and medication-related kidney stress compounds normal aging, the cumulative effect can accelerate decline significantly.
Kidney disease is called a silent disease because it rarely causes symptoms until significant damage has occurred. For people living with HIV — who face elevated risk from multiple directions — regular monitoring is not optional. It is how you catch the problem before it becomes irreversible.
HIV-Associated Nephropathy (HIVAN)
HIV-Associated Nephropathy — HIVAN — is a specific form of kidney disease caused directly by HIV infection of kidney cells[2]. It is a severe, potentially rapidly progressive form of kidney disease seen in people living with HIV, and without treatment it can progress to end-stage renal disease within months.
HIVAN has a striking racial disparity: it occurs almost exclusively in Black patients, and risk is strongly associated with carrying two APOL1 risk alleles, in combinations of the G1 and G2 variants that are more common in people with recent African ancestry[3]. It was one of the most devastating complications of advanced HIV disease in the pre-treatment era — and today, with effective ART, it is far less common. But it has not disappeared, and it remains a significant risk for Black people living with HIV who are not in care or not virally suppressed[4].
HIVAN — Key Facts
- Who is at risk: Primarily Black people living with HIV, particularly those with high viral loads or advanced HIV disease. Rarely occurs in virally suppressed patients.
- How it presents: Large amounts of protein in the urine (proteinuria), rapidly declining kidney function, swelling — often developing quickly over weeks to months
- Treatment: Effective ART is the primary treatment — suppressing HIV dramatically slows or halts HIVAN progression. In some cases, ACE inhibitors or ARBs are added to reduce proteinuria and protect kidney function
- Prognosis with treatment: Early ART can improve kidney outcomes, but existing scarring may be irreversible and some people progress despite treatment. Untreated HIVAN can progress rapidly. This is one of the strongest arguments for early HIV treatment — before kidney damage occurs.
ART Medications and the Kidneys
The relationship between antiretroviral therapy and kidney health is nuanced. ART is essential and the benefits dramatically outweigh the risks for the vast majority of people living with HIV. But certain medications have specific kidney effects that warrant monitoring — particularly in people with pre-existing risk factors. The DHHS HIV Clinical Guidelines lay out the current evidence and monitoring recommendations for each regimen[5].
ART Medications and Kidney Effects
- Tenofovir disoproxil fumarate (TDF) — in Truvada, Atripla, Cimduo, others: An important medication-related kidney concern. TDF is associated with proximal tubular toxicity — damage to the kidney tubules that reabsorb substances from filtered fluid[6]. Many people tolerate TDF well, but clinically important tubular injury or reduced filtration can occur. In people with pre-existing CKD, diabetes, hypertension, or low body weight, the risk is higher — and toxicity is exacerbated when TDF is combined with pharmacologic boosters like ritonavir or cobicistat[7]. Creatinine and urinalysis should be monitored regularly on TDF-containing regimens.
- Tenofovir alafenamide (TAF) — in Descovy, Biktarvy, Odefsey, others: A newer formulation of tenofovir that achieves equivalent antiviral effect at much lower plasma concentrations — significantly reducing kidney and bone toxicity[8]. For people with kidney risk factors, switching from TDF to TAF-based regimens is often considered. Renal eligibility depends on the specific combination and its creatinine-clearance criteria. Some TAF combinations can also be used in eligible adults receiving chronic hemodialysis. TAF has lower average renal toxicity than TDF, but still requires monitoring. Discuss the exact product with your HIV provider.[16]
- Atazanavir (Reyataz): Associated with kidney stone formation (nephrolithiasis) in some people — particularly those who are dehydrated or have other stone risk factors. Adequate hydration is important on atazanavir.
- Indinavir: An older protease inhibitor now rarely used — strongly associated with kidney stones and chronic kidney damage. Long-term survivors who took indinavir may have residual kidney effects.
- Creatinine changes with certain ART drugs: Cobicistat, dolutegravir, and bictegravir can cause a small early increase in creatinine by reducing its tubular secretion without reducing actual filtration. A new or continuing rise must still be evaluated for kidney injury; it should not automatically be dismissed as a drug effect.[17]
What to Monitor — Your Kidney Labs Explained
Kidney function monitoring is a standard part of HIV care — the schedule depends on your medicines, prior results, and kidney risk. HIVMA/IDSA recommends checking eGFR when ART starts or changes and at least twice yearly in stable patients, with urine testing at least annually and more often when indicated.[15] Knowing what the tests measure and what the numbers mean helps you participate in your own care. See the National Kidney Foundation's HIV and kidney disease overview for a plain-language guide[9].
| Lab Test | What It Measures | What to Know |
|---|---|---|
| Serum Creatinine | A waste product filtered by the kidneys — elevated levels suggest reduced filtration | Normal range varies by age, sex, and muscle mass. A trend upward over time is more meaningful than a single value. Cobicistat, dolutegravir, and bictegravir may increase creatinine without reducing true filtration; the timing and other kidney findings still need review. |
| eGFR (estimated Glomerular Filtration Rate) | Calculated estimate of how much blood the kidneys filter per minute — the primary measure of kidney function | An eGFR below 60 mL/min/1.73m² for more than three months is one criterion for CKD. CKD can also occur at higher eGFR when persistent kidney-damage markers are present. A single low result needs evaluation and does not by itself establish chronic disease. An eGFR below 15 is the kidney-failure range.[14] |
| Urinalysis (with microscopy) | Screens urine for protein, blood, glucose, and other markers of kidney or urinary tract disease | Protein in the urine (proteinuria) is one of the earliest signs of kidney damage — including HIVAN. Should be checked at least annually for people living with HIV. |
| Urine Protein-to-Creatinine Ratio (UPCR) | Quantifies how much protein is leaking into the urine — a more precise measure than qualitative urinalysis | Used to monitor patients with known proteinuria or high CKD risk. Significant proteinuria warrants nephrology referral. |
| Urine Phosphate / Tubular Markers | Measures of tubular function — relevant specifically for monitoring TDF toxicity | Tubular dysfunction from TDF can appear before eGFR declines. If you're on TDF and have risk factors, ask whether tubular markers are being checked. |
| Blood Pressure | Not a kidney lab per se — but hypertension is both a cause and a consequence of CKD | Target blood pressure in CKD is generally below 130/80. Know your numbers at every visit. |
Symptoms of Kidney Disease — Don't Wait for Them
Early and moderate kidney disease typically causes no symptoms. By the time symptoms appear — swelling in the legs and ankles, fatigue, decreased urine output, nausea, confusion — significant damage has usually already occurred. This is why regular lab monitoring matters. Don't wait to feel sick to ask about your kidney numbers.
Protecting Your Kidneys — What You Can Control
Evidence-based kidney protection strategies
- Stay virally suppressed: The most important kidney protection is controlling HIV itself. Viral suppression greatly reduces HIVAN risk and HIV-driven kidney injury, but does not eliminate every risk of kidney disease[4]. Staying undetectable also means Undetectable = Untransmittable (U=U)[10] — the same viral suppression that protects your kidneys is what makes HIV sexually untransmittable. ART is kidney-protective when it replaces uncontrolled viral replication.
- Control blood pressure: Target below 130/80. If blood pressure medication is needed, ACE inhibitors or ARBs are particularly useful when CKD includes clinically significant albuminuria or suspected HIVAN, if appropriate for the person. Discuss with your provider.
- Manage diabetes: If you have diabetes, tight glycemic control slows CKD progression. SGLT2 inhibitors — a class of diabetes medication — have specific evidence for kidney protection in diabetic CKD and are increasingly used in people living with HIV.
- Stay hydrated: Avoid dehydration, especially if you are prone to stones. If you have advanced CKD, heart failure, or a prescribed fluid limit, follow your care team’s individualized fluid advice.
- Avoid nephrotoxic medications: NSAIDs (ibuprofen, naproxen) reduce blood flow to the kidneys and can cause acute kidney injury — particularly in people with pre-existing CKD or dehydration. Use with caution and discuss with your provider. IV contrast dye (used in some CT scans) can also be nephrotoxic — always tell your provider about any kidney issues before imaging with contrast.
- Treat HCV if coinfected: Curing HCV with direct-acting antivirals removes a significant independent driver of kidney damage.
- Discuss TDF vs TAF with your provider: If you have kidney risk factors and are on a TDF-containing regimen, ask whether a TAF-based alternative is appropriate for you.
If CKD Is Diagnosed — What Comes Next
A diagnosis of chronic kidney disease needs an individualized evaluation; rapid changes or severe symptoms may require urgent care. Many people with CKD stages 1–3 (eGFR at least 30) live well for decades without progression to kidney failure, particularly with good management of the contributing factors. What matters is catching it, understanding it, and managing it systematically.
CKD management for people living with HIV
- Nephrology referral: Referral is particularly important for a persistent substantial decline in filtration, heavy albuminuria, blood in the urine with other kidney abnormalities, or eGFR below 30. An isolated value below 60 is not a universal referral rule; the trend and clinical findings matter. A nephrologist who has experience with HIV is ideal — major HIV centers typically have this collaboration established.
- ART regimen review: CKD diagnosis should trigger a review of your ART regimen with your HIV provider. TDF-containing regimens may need to be switched. Dose adjustments may be needed for certain medications as kidney function declines.
- Dietary modifications: Dietary changes depend on kidney function, laboratory results, medicines, and nutritional needs. Potassium and phosphorus restriction are not automatic for everyone with CKD. A renal dietitian can tailor sodium, protein, and other recommendations without compromising nutrition.
- Anemia management: CKD reduces erythropoietin production, leading to anemia — which can compound HIV-related fatigue. This is treatable and should be monitored.
- Kidney transplant: For people living with HIV who progress to end-stage renal disease, kidney transplant is now an established option. Outcomes for transplant recipients living with HIV have improved dramatically, and transplantation is no longer withheld on the basis of HIV status alone[11]. Under the HOPE Act, HIV-to-HIV kidney transplantation is permitted — and following 2024 federal regulatory changes and June 2025 OPTN policy updates, HIV-to-HIV kidney transplants are no longer restricted to research protocols[12].
Florida In Focus — Kidney Care for People Living with HIV
🌴 Florida In Focus: Kidney Health
University of Miami — HIV and Nephrology: The University of Miami has integrated HIV and nephrology expertise, with specific experience in HIVAN and CKD care for people living with HIV. For complex kidney disease in South Florida, UM is the primary academic referral center.
University of Florida Health (Gainesville): UF Health's nephrology program has experience managing kidney disease in people living with HIV. For patients in North and Central Florida, UF Health or Jacksonville's UF Health campus are key referral destinations.
Ryan White kidney care coverage: Nephrology visits and kidney-related lab monitoring are covered services under the Ryan White HIV/AIDS Program for eligible people living with HIV[13]. Ask your Ryan White case manager whether nephrology referral and specialist visits are covered in your program.
National Kidney Foundation of Florida: Offers education and assistance for eligible Florida patients with kidney disease. Ask your social worker about the Direct Aid program. kidneyfl.org — patient support →
Dialysis access: If you have reached end-stage renal disease and require dialysis, federally funded dialysis centers cannot discriminate on the basis of HIV status. All dialysis centers must follow standard infection control protocols that are safe for people living with HIV.
Use the RiseUpToHIV Florida Locator to find HIV specialty care near you — and ask your HIV provider about nephrology coordination.
References & Sources
- Mocroft A et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS (2010), EuroSIDA cohort — examines CKD and antiretroviral exposure among people with HIV; it does not establish a matched-population 2–4× risk estimate. PubMed ↩
- Atta MG et al. HIV-associated nephropathy patients with and without apolipoprotein L1 gene variants have similar clinical and pathological characteristics. Kidney International (2012). A study of biopsy-proven HIVAN; management guidance is provided in reference 15. PMC ↩
- Kasembeli AN et al. APOL1 Risk Variants Are Strongly Associated with HIV-Associated Nephropathy in Black South Africans. Journal of the American Society of Nephrology. PMC · NIH: gene variant news release ↩
- Ray PE. Progression of HIV-1 CKDs: Viral Load Versus APOL1 Risk Alleles. Kidney International Reports (2025), commentary. Discusses the role of viral control and APOL1 risk in CKD progression; suppression does not guarantee that all progression stops. PMC ↩
- U.S. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Clinicalinfo.HIV.gov. clinicalinfo.hiv.gov ↩
- Fernandez-Fernandez B et al. Tenofovir Nephrotoxicity: 2011 Update. AIDS Research and Treatment — mechanism of TDF proximal tubular toxicity. PMC ↩
- Ryom L et al. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. Journal of Infectious Diseases. Boosted TDF regimens carry higher renal risk than unboosted. PubMed ↩
- Sax PE et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate: renal and bone safety. Clinical trial data showed lower plasma tenofovir and reduced renal/bone biomarker changes with TAF. Summarized in DHHS ARV Guidelines (see fn 5). PubMed ↩
- National Kidney Foundation. HIV and Kidney Disease. Plain-language patient guide. kidney.org ↩
- Centers for Disease Control and Prevention. HIV Treatment as Prevention (U=U). cdc.gov ↩
- Durand CM et al. Safety of Kidney Transplantation from Donors with HIV. New England Journal of Medicine — outcomes for HIV-to-HIV kidney transplants comparable to HIV-negative donor sources. PMC ↩
- OPTN / HRSA. HOPE Act Policy Update, effective June 26, 2025 — removes research-protocol requirement for HIV-to-HIV liver and kidney transplants. hrsa.gov (PDF) · HIV.gov background: HIV.gov ↩
- Health Resources and Services Administration. Ryan White HIV/AIDS Program — Core Medical Services and Specialty Care. ryanwhite.hrsa.gov ↩
- National Kidney Foundation — Criteria for chronic kidney disease. ↩
- HIVMA/IDSA — Chronic kidney disease in people with HIV (2014 guideline). ↩
- NIH — Antiretroviral dosing in renal and hepatic insufficiency. ↩
- NIH — Common and severe adverse effects of antiretroviral medications. ↩